Michael Zand – Page 342

A combination of cancer immunotherapies could save more lives – Medical Xpress

2018-03-27 Michael Zand NEWS

Monsanto is on the verge of producing the first fruit made with a blockbuster gene-editing tool that could … – Business Insider

Business InsiderMonsanto is on the verge of producing the first fruit made with a blockbuster gene-editing tool that could …Business InsiderThe alliance could tee-up Monsanto, long known for its controversial dealings with farmers and its role in pop… Continue reading

2018-03-27 Michael Zand NEWS

CRISPR Adapted to Prevent Unwanted Mutations – Genetic Engineering & Biotechnology News

CRISPR Adapted to Prevent Unwanted MutationsGenetic Engineering & Biotechnology NewsA single-base substitution in the DNA code can turn a normal cell cancerous, or convert an antibiotic-sensitive bacterium into one that is antibiotic resistant. Scienti… Continue reading

2018-03-27 Michael Zand NEWS

A combination of cancer immunotherapies could save more lives – EurekAlert (press release)

Medical XpressA combination of cancer immunotherapies could save more livesEurekAlert (press release)The pre-clinical study, published in Clinical Cancer Research, by Dr Sarah Buchan and colleagues, combined antibodies targeting PD-1/PD-L1, a type of i… Continue reading

2018-03-27 Michael Zand NEWS

A combination of cancer immunotherapies could save more lives – EurekAlert (press release)

A combination of cancer immunotherapies could save more livesEurekAlert (press release)The pre-clinical study, published in Clinical Cancer Research, by Dr Sarah Buchan and colleagues, combined antibodies targeting PD-1/PD-L1, a type of immunotherapy k… Continue reading

2018-03-27 Michael Zand NEWS

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA Tx – Monthly Prescribing Reference

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA TxMonthly Prescribing ReferenceHealthDay News — Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a… Continue reading

2018-03-27 Michael Zand NEWS

Vigil immunotherapy tolerated well for recurrent ovarian CA Tx – Medical Xpress

Medical XpressVigil immunotherapy tolerated well for recurrent ovarian CA TxMedical Xpress(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a signi… Continue reading

2018-03-27 Michael Zand NEWS

1
…
340
341
342
343
344
…
3,823

Medical Xpress

A combination of cancer immunotherapies could save more lives
Medical Xpress
Dr Catherine Pickworth, from Cancer Research UK, said: “Immunotherapy treatments are already showing huge promise for a number of cancer types, but they don’t work for everyone. This work in mice suggests that using two types of immunotherapy could be …

and more »

Login

Cart

All posts by: Michael Zand

Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC – Targeted Oncology

A combination of cancer immunotherapies could save more lives – Medical Xpress

Monsanto is on the verge of producing the first fruit made with a blockbuster gene-editing tool that could … – Business Insider

CRISPR Adapted to Prevent Unwanted Mutations – Genetic Engineering & Biotechnology News

A combination of cancer immunotherapies could save more lives – EurekAlert (press release)

A combination of cancer immunotherapies could save more lives – EurekAlert (press release)

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA Tx – Monthly Prescribing Reference

Vigil immunotherapy tolerated well for recurrent ovarian CA Tx – Medical Xpress